Skip to content
MarketScale
‹ Back to IndustriesSciences

Scientists Create Efficient Artificial Photosynthesis, and the Promise of Clean Energy

Photosynthesis is one of the most efficient ways known to harvest solar energy to convert into chemical energy. As such, it’s a demonstration of how nature has succeeded through the process of natural selection where we have failed through rational construction and experimentation in trying to create artificial photosynthesis. That is, until now.  The Proceedings…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share

Key takeaways

01

Photosynthesis is one of the most efficient ways known to harvest solar energy to convert into chemical energy.

02

As such, it’s a demonstration of how nature has succeeded through the process of natural selection where we have failed through rational construction and experimentation in trying to create artificial photosynthesis.

Photosynthesis is one of the most efficient ways known to harvest solar energy to convert into chemical energy. As such, it’s a demonstration of how nature has succeeded through the process of natural selection where we have failed through rational construction and experimentation in trying to create artificial photosynthesis. That is, until now. 

The Proceedings of the National Academy of Science recently published a paper explaining how a team of scientists from the U.S. and China have created a simple catalyst capable of using sunlight to oxidize water into oxygen and hydrogen gases. This catalyst is simply two iridium atoms connected by a single oxygen atom (Ir2O), all of which are on an α-Fe2O3 substrate (α-Fe2O3 is found in nature as hematite, also known as the main form of iron ore). The result is a form of photosynthesis that is similar to natural photosynthesis, but at lower cost and higher efficiencies. 

The Ir2O catalyst is simple, durable, and highly active, and it not only harvests solar energy, but it also stores that energy in chemical bonds. If these catalysts can be scaled up to truly commercial levels of hydrogen gas production, they could radically transform energy production across the globe. After all, the product of these stable iridium dinuclear catalysts—hydrogen gas—is an important alternative fuel precisely because it produces substantial energy when burned with oxygen to create water. A hydrogen-fueled economy would be one that can provide everyone with the fuel and energy we need, without creating any pollution byproducts. These new catalysts thus offer significant hope and promise. 

Unfortunately, iridium is one of the rarest metals on earth, with annual global production at only around 3 tons. While sparse in the earth’s crust, iridium is much more common in meteorites—although mining meteorites won’t happen in the immediate future. This rare metal has found a recent increase in use in a variety of electronics, spark plugs, and devices that need to withstand very high temperatures. Because this iridium dinuclear catalyst is so efficient, however, the scarcity of iridium will hopefully not pose a problem to the further development of these photosynthetic cells.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512